According to the company, the ability to fund both the Type 1 diabetes and GVHD human clinical trials are subject to the company raising additional capital in the near term.
The company plans to conduct a placebo-controlled Type 1 diabetes human clinical trial in recently diagnosed juvenile subjects.
Omni Bio also intends to initiate a proof of principle human clinical trial for the treatment of lethal complication of bone marrow transplantation.
Omni Bio CEO James Crapo said the plan to complete a placebo-controlled study is next step in its commercial strategy for AAT treatment of recently diagnosed Type 1 diabetics.
"The commencement of a human clinical trial for the treatment or prevention of GVHD is aligned with the treatment of Type 1 diabetes, as both are autoimmune diseases," Crapo added.